PMID- 22026157
OWN - NLM
STAT- MEDLINE
DCOM- 20111202
LR  - 20111026
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 66
IP  - 10
DP  - 2011 Oct
TI  - Generation of a liver targeting fusion interferon and its bioactivity analysis in 
      vitro.
PG  - 761-5
AB  - The objective of this study was to generate a liver targeting fusion interferon, 
      galactosyl-human serum albumin-interferon alpha2b (G-HSA-IFN) and to evaluate its 
      bioactivity in vitro on HepG2.2.15 cells which express hepatitis B surface 
      antigen (HBsAg) and hepatitis B e antigen (HBeAg). The cell proliferation was 
      determined by Sulpho Rhodamine B (SRB) staining method and flow cytometry (FCM) 
      assay. Hochest33342 and Propidium Iodide (PI) double staining and Western blot 
      analysis of Bcl-2/Bax were also performed to evaluate cell lethality and 
      apoptosis. The concentrations of HBsAg and HBeAg secreted in culture supernatant 
      were detected using Enzyme-Linked Immunosorbent Assay (ELISA). The results 
      demonstrated that G-HSA-IFN could inhibit the proliferation of HepG2.2.15 cells 
      and the cell cycle was arrested at G0/G1 phase. Western blotting results showed 
      that the expression of Bcl-2 was inhibited in a dose-dependent manner while the 
      expression of Bax was enhanced. The expression of HBsAg was inhibited by 
      G-HSA-IFN in a dose-dependent manner, while no significant inhibiting effect on 
      the expression of HBeAg was observed. Conclusively, G-HSA-IFN could not only 
      significantly inhibit the HBsAg expression and the proliferation of HepG2.2.15 
      cells, but also induce the apoptosis of the target cells, rendering it a 
      promising drug candidate for hepatitis B.
FAU - Cai, Gangming
AU  - Cai G
AD  - Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of 
      Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China.
FAU - Jiang, Mengjun
AU  - Jiang M
FAU - Zhou, Yaoyuan
AU  - Zhou Y
FAU - Gu, Xiaobo
AU  - Gu X
FAU - Zhang, Bo
AU  - Zhang B
FAU - Zou, Meifen
AU  - Zou M
FAU - Zhou, Xingqin
AU  - Zhou X
FAU - Bao, Jiandong
AU  - Bao J
FAU - Cao, Guoxian
AU  - Cao G
FAU - Zhang, Rongjun
AU  - Zhang R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Antiviral Agents)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (Interferon-alpha)
SB  - IM
MH  - Antiviral Agents/*administration & dosage/*pharmacokinetics/pharmacology
MH  - Apoptosis/drug effects
MH  - Blotting, Western
MH  - Cell Cycle/drug effects
MH  - Cell Death/drug effects
MH  - Cell Line
MH  - Cell Proliferation/drug effects
MH  - *Drug Delivery Systems
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Hepatitis B Surface Antigens/analysis/biosynthesis
MH  - Hepatitis B e Antigens/analysis/biosynthesis
MH  - Humans
MH  - Interferon-alpha/*administration & dosage/*pharmacokinetics/pharmacology
MH  - Liver/drug effects/*metabolism
MH  - Microscopy, Fluorescence
MH  - S Phase/drug effects
EDAT- 2011/10/27 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/10/27 06:00
PHST- 2011/10/27 06:00 [entrez]
PHST- 2011/10/27 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PST - ppublish
SO  - Pharmazie. 2011 Oct;66(10):761-5.